Sino Biopharmaceutical Limited (HKG:1177)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.890
-0.060 (-1.52%)
Apr 3, 2025, 4:08 PM HKT
30.98%
Market Cap 70.63B
Revenue (ttm) 30.72B
Net Income (ttm) 3.72B
Shares Out 17.88B
EPS (ttm) 0.20
PE Ratio 35.39
Forward PE 20.82
Dividend 0.08 (2.03%)
Ex-Dividend Date Jun 16, 2025
Volume 137,201,524
Average Volume 109,370,322
Open 3.910
Previous Close 3.950
Day's Range 3.810 - 3.980
52-Week Range 2.290 - 4.250
Beta 0.75
RSI 68.77
Earnings Date Mar 27, 2025

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbei... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 24,379
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1177
Full Company Profile

Financial Performance

In 2024, Sino Biopharmaceutical's revenue was 28.87 billion, an increase of 10.18% compared to the previous year's 26.20 billion. Earnings were 3.50 billion, an increase of 50.08%.

Financial numbers in CNY Financial Statements

News

Sino Biopharmaceutical Limited goes ex-dividend tomorrow

Sino Biopharmaceutical Limited (SBHMY) declares $0.0653/share quarterly dividend, payable Oct. 18 for shareholders of record Sept. 12.

7 months ago - Seeking Alpha

Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln

Hong Kong-listed Sino Biopharmaceutical will sell a 67% stake in unit CP Pharmaceutical (Qingdao) for 1.82 billion yuan ($253.28 million) to entities controlled by state-owned Guoxin Group, the compan...

1 year ago - Reuters

China's health-care sector may be next to face regulatory crackdown, says economist

Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...

3 years ago - CNBC International TV

Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea

Cancer killed far more people around the world than Covid-19 in 2020

4 years ago - Forbes

Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day

JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech reporte...

4 years ago - Seeking Alpha